Canada population norms for the EQ-5D-5L

Yan, Jiajun; Xie, Song; Johnson, Jeffrey; Pullenayegum, Eleanor; Öhinmaa, Arto; Bryan, Stirling; Xie, Feng

doi:10.1007/s10198-023-01570-1

Cited by 8 publications

(8 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are many instruments available to measure health-related quality of life, including the VR-12 and related instruments (VR-36, SF-12, SF-36), EQ-5D instruments (EQ-5D-3L and EQ-5D-5L), the Health Utilities Index (HUI), and the PROMIS Global-10. There are Canadian population norms for the HUI3 [ 13 ], EQ-5D-3L (Alberta only) [ 18 ], EQ-5D-5L [ 19 , 20 ], SF-12 (Alberta only) [ 18 ], SF-6Dv2 (Quebec only, with UK-derived preference weights) [ 21 ], and the SF-36 [ 37 ]. The Canadian Institute for Health Information (CIHI) recommends that the availability of population norms be a central consideration when choosing between available measures [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

“…For example, studies of the SF-6D from the UK, Australia, Hong Kong, and China, estimated mean values ranging from 0.766 to 0.872 [ 49 – 53 ]. A Canadian study of the HUI estimated a mean health utility value of 0.863 [ 13 ], while Canadian, Chinese, and US studies of the EQ-5D-5L estimated mean values of 0.864, 0.946 and 0.851 (from the face-to-face sample), respectively [ 20 , 52 , 54 ]. Conversely, our estimates are similar to Australian mean age- and sex-adjusted utility norms for the Assessment of Quality of Life six-dimension (AQoL-6D) and eight-dimension (AQoL-8D) instruments, which were 0.737 and 0.680, respectively [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

“…There are no Canadian population norms for the VR-12. Previous studies have published Canadian population norms for health utility scores generated using other instruments, including the Health Utilities Index Mark 3 (HUI3) [ 13 ], EQ-5D-3L (Alberta only) [ 18 ], EQ-5D-5L [ 19 , 20 ], and, for Quebec only, the SF-6Dv2 (albeit with preference weights derived from a representative sample of the United Kingdom (UK) population) [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Quality of life of the Canadian population using the VR-12: population norms for health utility values, summary component scores and domain scores

Trenaman,

Guh,

Bansback

et al. 2023

Qual Life Res

View full text Add to dashboard Cite

Objectives To estimate Canadian population norms (health utility values, summary component scores and domain scores) for the VR-12. Methods English and French speaking Canadians aged 18 and older completed an online survey that included sociodemographic questions and standardized health status instruments, including the VR-12. Responses to the VR-12 were summarized as: (i) a health utility value; (ii) mental and physical component summary scores (MCS and PCS, respectively), and (iii) eight domain scores. Norms were calculated for the full sample and by gender, age group, and province/territory (univariate), and for several multivariate stratifications (e.g., age group and gender). Results were summarized using descriptive statistics, including number of respondents, mean and standard deviation (SD), median and percentiles (25th and 75th), and minimum and maximum. Results A total of 6761 people who clicked on the survey link completed the survey (83.4% completion rate), of whom 6741 (99.7%) were included in the analysis. The mean health utility score was 0.698 (SD = 0.216). Mean health utility scores tended to be higher in older age groups, ranging from 0.661 (SD = 0.214) in those aged 18–29 to 0.728 (SD = 0.310) in those aged 80+. Average MCS scores were higher in older age groups, while PCS scores were lower. Females consistently reported lower mean health utility values, summary component scores and domain scores compared with males. Conclusions This is the first study to present Canadian norms for the VR-12. Health utility norms can serve as a valuable input for Canadian economic models, while summary component and domain norms can help interpret routinely-collected data.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Quality of life of the Canadian population using the VR-12: population norms for health utility values, summary component scores and domain scores

Trenaman,

Guh,

Bansback

et al. 2023

Qual Life Res

View full text Add to dashboard Cite

show abstract

“…Age-specific utilities for the general population were based on EQ-5D-5L index scores for the Canadian population (31). QALY losses associated with the modelled health outcomes were derived from published studies and assumption (32)(33)(34)(35)(36).…”

Section: Model Overviewmentioning

confidence: 99%

Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysis

Tuite,

Simmons,

Rudd

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Vaccines against respiratory syncytial virus (RSV) have the potential to reduce disease burden and costs in Canadians, but the cost-effectiveness of RSV vaccination programs for older adults is unknown. We evaluated the cost-effectiveness of different adult age cutoffs for RSV vaccination programs, with or without a focus on people with higher disease risk due to chronic medical conditions (CMCs). Methods: We developed a static individual-based model of medically-attended RSV disease to evaluate the cost-utility of alternate age-, medical risk-, and age- plus medical risk-based vaccination policies. The model followed a multi-age cohort of 100,000 people aged 50 years and older over a three-year period. Vaccine characteristics were based on RSV vaccines authorized in Canada as of March 2024. We calculated incremental cost-effectiveness ratios (ICERs) in 2023 Canadian dollars per quality-adjust life year (QALY) from the health system and societal perspectives, discounted at 1.5%. Results: Although all vaccination strategies averted medically-attended RSV disease, strategies focused on adults with CMCs were more likely to be cost-effective than age-based strategies. A program focused on vaccinating adults aged 70 years and older with one or more CMCs was optimal for a cost-effectiveness threshold of $50,000 per QALY. Results were sensitive to assumptions about vaccine price, but approaches based on medical risk remained optimal compared to age-based strategies even when vaccine prices were low. Findings were robust to a range of alternate assumptions. Interpretation: Based on available data, RSV vaccination programs in some groups of older Canadians with underlying medical conditions are expected to be cost-effective.

show abstract

“…The utility values were measured in the quality-adjusted life year (ranging from 0 [death] to 1 [perfectly healthy]) using EQ-5D (Balestroni and Bertolotti, 2012). We obtained the baseline population average utility values for the Canadian population from a recent study (Yan et al, 2024). As this study does not provide the utility values for less than 18 years of age, we made an assumption that the utility values started at 1 at birth and linearly interpolated to 18 years of age for each sex (where the utilities were 0.881 for females and 0.875 for males).…”

Section: Model Componentsmentioning

confidence: 99%

Development and Validation of an Asthma Policy Model for Canada: Lifetime Exposures and Asthma outcomes Projection (LEAP)

Lee,

Petkau,

Johnson

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: To develop Lifetime Exposures and Asthma outcomes Projection (LEAP), a reference policy model for evaluating health outcomes and costs of asthma interventions and policies for the Canadian population. Methods: Following the best practice guidelines for development, we first created a conceptual map with a steering committee of clinician experts and economic modelers through a modified Delphi-process. Following the committee's recommendations and given the multidimensionality of risk factors and the need for modeling realistic aspects (e.g., gradual market penetration) of adopting health technologies, we opted for an open-population microsimulation design. For the first version of the model, we concentrated on several key risk factors (age, sex, family history of asthma at birth, and exposure to antibiotics in the first year of life) from the concept map. The model consists of five intertwined modules: 1) demographic, 2) risk factors, 3) asthma occurrence, 4) asthma outcomes, and 5) payoffs. The demographic module, including birth, mortality, immigration, and emigration, was based on sex- and age-specific estimates and projections from Statistics Canada. The distributions of risk factors, including family history of asthma and exposure to antibiotics, were estimated from population-based administrative databases and a population-based longitudinal birth cohort. To estimate parameters in the asthma occurrence (prevalence, incidence, reassessment) and asthma outcomes (severity, symptom control, exacerbations) modules, we performed quantitative evidence synthesis. Costs and utility weights were obtained from the literature. We conducted multiple face and internal validation assessments. Results: LEAP is capable of modeling asthma-related health outcomes at the individual and aggregate levels from 2001 onwards. Face validity was confirmed by checking the structure, equations, codes, and results. We calibrated and internally validated the age-sex stratified demographic projections to the estimates and projections from Statistics Canada, the age-sex stratified asthma prevalence to the administrative data, and the asthma control levels and exacerbation rates to the estimates from the literature. Conclusions: LEAP is the first reference Canadian asthma policy model that emerged from identified needs for health policy planning for early interventions in asthma. As an open-source and open-access platform, LEAP can provide a unified framework under which different interventions and policies can be consistently compared to identify those with the highest value proposition.

show abstract

Canada population norms for the EQ-5D-5L

Cited by 8 publications

References 47 publications

Quality of life of the Canadian population using the VR-12: population norms for health utility values, summary component scores and domain scores

Quality of life of the Canadian population using the VR-12: population norms for health utility values, summary component scores and domain scores

Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysis

Development and Validation of an Asthma Policy Model for Canada: Lifetime Exposures and Asthma outcomes Projection (LEAP)

Contact Info

Product

Resources

About